Articoli con mandati relativi all'accesso pubblico - Pedro Dorado (0000-0003-4100-721X)Ulteriori informazioni
Non disponibili pubblicamente: 13
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients
EM Penas-Lledo, HD Trejo, P Dorado, A Ortega, H Jung, E Alonso, ...
Molecular psychiatry 18 (1), 8-9, 2013
Mandati: Government of Spain
CYP2D6 and The Severity of Suicide Attempts
EM Penas-Lledo, H Blasco-Fontecilla, P Dorado, C Vaquero-Lorenzo, ...
Pharmacogenomics 13 (2), 179-184, 2012
Mandati: Government of Spain
Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF …
MEG Naranjo, F Rodrigues-Soares, EM Penas-Lledo, E Tarazona-Santos, ...
Omics: a journal of integrative biology 22 (9), 575-588, 2018
Mandati: Government of Spain
Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
A Llerena, M Alvarez, P Dorado, I González, E Peñas-LLedó, B Pérez, ...
The pharmacogenomics journal 14 (3), 229-234, 2014
Mandati: Government of Spain
CYP2D6 -1584C>G Promoter Polymorphism and Debrisoquine Ultrarapid Hydroxylation in Healthy Volunteers
A LLerena, P Dorado, R Ramírez, LR Calzadilla, E Penas-LLedo, ...
Pharmacogenomics 14 (16), 1973-1977, 2013
Mandati: Government of Spain
Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6
N González-Vacarezza, F Abad-Santos, A Carcas-Sansuan, P Dorado, ...
The pharmacogenomics journal 13 (5), 452-455, 2013
Mandati: Government of Spain
Relationship between the CYP2C9 IVS8-109A>T Polymorphism and High Losartan Hydroxylation in Healthy Ecuadorian Volunteers
P Dorado, A Gallego, E Peñas-LLedó, E Terán, A LLerena
Pharmacogenomics 15 (11), 1417-1421, 2014
Mandati: Government of Spain
CYP2D6Genetic Polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
M Lopez-Lopez, E Penas-Lledo, P Dorado, A Ortega, T Corona, A Ochoa, ...
Pharmacogenomics 15 (15), 1859-1865, 2014
Mandati: Government of Spain
Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
I Rodeiro, D Remírez-Figueredo, M García-Mesa, P Dorado, A LLerena, ...
Walter de Gruyter 27 (1), 57-60, 2012
Mandati: Government of Spain
Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
I Fricke-Galindo, A Ortega-Vázquez, N Monroy-Jaramillo, P Dorado, ...
Pharmacogenomics 17 (17), 1913-1930, 2016
Mandati: Government of Spain
CYP2D6 ethnic variability in Hispanics
A LLerena, P Dorado, MEG Naranjo, E Peñas-Lledó
Future Science Ltd, 2014
Mandati: Government of Spain
Eating disorder symptoms and CYP2D6 variation in Cuban healthy females: a report from the Ibero-American Network of Pharmacogenetics
E M Penas-LLedo, I González, P Dorado, B Pérez, L R Calzadilla, ...
Current Pharmacogenomics and Personalized Medicine (Formerly Current …, 2012
Mandati: Government of Spain
Research Highlights: Novel CYP2C9 Genetic Polymorphisms and Assessment of their Impact On Hydroxylation Capacity
P Dorado, EM Peñas-LLedo, A LLerena
Pharmacogenomics 15 (3), 261-264, 2014
Mandati: Government of Spain
Disponibili pubblicamente: 27
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
A Llerena, P Dorado, R Ramírez, I González, M Alvarez, EM Peñas-Lledó, ...
The pharmacogenomics journal 12 (2), 176-183, 2012
Mandati: Government of Spain
High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
EM Peñas-Lledó, P Dorado, Z Agüera, M Gratacós, X Estivill, ...
Mol Psychiatry 16 (7), 691-2, 2011
Mandati: Government of Spain
Prevalence of potential drug–drug interaction risk among chronic kidney disease patients in a Spanish hospital
G Santos-Díaz, AM Pérez-Pico, MÁ Suárez-Santisteban, V García-Bernalt, ...
Pharmaceutics 12 (8), 713, 2020
Mandati: Government of Spain
CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
P Dorado, N Heras, E Machín, F Hernández, E Teran, A LLerena
European journal of clinical pharmacology 68, 637-644, 2012
Mandati: Government of Spain
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
P Dorado, E López-Torres, EM Peñas-Lledó, J Martínez-Antón, A Llerena
The pharmacogenomics journal 13 (4), 359-361, 2013
Mandati: Government of Spain
CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
B Almoguera, R Riveiro-Alvarez, J Lopez-Castroman, P Dorado, ...
Pharmacogenetics and genomics 23 (11), 627-630, 2013
Mandati: Government of Spain
CYP2D6 polymorphism in patients with eating disorders
EM Peñas-Lledó, P Dorado, Z Agüera, M Gratacós, X Estivill, ...
The pharmacogenomics journal 12 (2), 173-175, 2012
Mandati: Government of Spain
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software